5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)
Recruiting
N/A
Interventional Study
LARS - Low Anterior Resection Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 212 (estimated)
- Sponsor
- Seoul National University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* mid and low rectal cancer (AV\<15cm)
* stage II, III, preop long-course CCRT, then ileostomy repair
* about 1\~12 months after operation (no stomy)
* about 1\~6 months after ileostomy repair
* major LARS
Exclusion Criteria:
* recurred rectal cancer
* stage IV
* IBD
* uncontr…
Contacts
No contact information available.